While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

A spokesperson confirmed the company plans to reduce its workforce by “less than 20%,” months after significantly lowering ...

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled ...

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, ...

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place ...

An executive order President Trump signed Thursday codifies rates for over 60 trading partners, including Switzerland. A ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

Pfizer's Albert Bourla told investors that major drugmakers are "ready to to roll up their sleeves" and build out more direct ...